Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin

J. F. Gallegos-Orozco, A. Loaeza-del Castillo, A. P. Fuentes, M. García-Sandoval, L. Soto, R. Rodríguez, M. C. Gutiérrez-Ruíz, G. Gutiérrez-Reyes, A. Bonder, M. A. Olivera, David Kershenobich

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Background: Interferon-based therapy induces changes in viral dynamics in chronic hepatitis C (CHC) patients. Aims: The aim of this study was to assess early hepatitis C virus (HCV)-RNA changes and evaluate its predictive value to achieve sustained viral response (SVR) in patients with CHC treated with peginterferon α-2b weekly plus ribavirin daily for 48 weeks. Methods: HCV-RNA was measured at baseline, 48 h, 4, 12, 24 and 48 weeks of treatment and 24 weeks after treatment. Results: Eighteen HCV genotype 1 patients were included (13 male, five female) with a mean age of 44.4 ± 11.9 years. Nine patients achieved SVR (50%). Viral decline occurred as early as 48 h; the magnitude of decline was statistically different between both groups (P <0.01). Responders had a ≥ 1 log10 drop in HCV-RNA at 48 h (positive predictive value (PPV) of 89% to achieve SVR) that persisted at week 4. By week 12, serum HCV-RNA was undetectable (PPV 100%). Conclusions: Our data indicate that peginterferon α-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon α-2b and that these changes are useful in predicting response to therapy in CHC patients.

Original languageEnglish (US)
Pages (from-to)91-95
Number of pages5
JournalLiver International
Volume25
Issue number1
DOIs
StatePublished - Feb 2005

Keywords

  • Early viral response
  • HCV
  • Peginterferon α-2b
  • Sustained viral response
  • Viral dynamics

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin'. Together they form a unique fingerprint.

  • Cite this

    Gallegos-Orozco, J. F., Loaeza-del Castillo, A., Fuentes, A. P., García-Sandoval, M., Soto, L., Rodríguez, R., Gutiérrez-Ruíz, M. C., Gutiérrez-Reyes, G., Bonder, A., Olivera, M. A., & Kershenobich, D. (2005). Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin. Liver International, 25(1), 91-95. https://doi.org/10.1111/j.1478-3231.2005.1040.x